Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Remdesivir Races Through EU Review

Executive Summary

Gilead Sciences’ remdesivir could get the nod from the European Medicines Agency this week as a treatment for COVID-19, paving the way for swift EU approval.

You may also be interested in...



Remdesivir’s EU Approval For COVID-19 Due Within Days

Moment Of Truth For Belantamab Mafodotin, Trikafta And Turalio At EMA

A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.

Gilead Files For Remdesivir Approval In EU

The much-anticipated EU filing for Gilead’s COVID-19 treatment is being reviewed quickly by the European Medicines Agency.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel